Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.

Haider Al-JanabiKaty MoyesRichard AllenMatthew FisherMateus CrespoBora GurelPasquale RescignoJohann de BonoHarry NunnsChristopher BaileyAnna Junker-JensenMunitta MuthanaWayne A PhillipsHelen B PearsonMary-Ellen TaplinJanet E BrownClaire E Lewis

Published in: Journal for immunotherapy of cancer (2024)

Together, our data indicate that targeting a STING agonist to PV TAMs could be used to extend the treatment window for ADT in prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
cancer therapy
electronic health record
big data
stem cells
benign prostatic hyperplasia
replacement therapy
artificial intelligence